UCB's Cimzia approved for RA in the US
This article was originally published in Scrip
Executive Summary
UCB's pegylated anti-TNF drug Cimzia (certolizumab pegol) has received US approval for the treatment of rheumatoid arthritis, as a monotherapy or in combination with methotrexate.